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study were 1) to determine whether there was an associ-
ation between drug costs and medical costs for type 1 dia-
betes patients and, 2) to develop a regression model that
predicts medical costs from drug costs. METHODS: The
records of 315 patients enrolled in a large mid-western
health care plan were reviewed for a 1-year period. The
drug costs included insulin costs and oral diabetes drug
costs. The medical costs included all paid services for
primary and secondary diagnosis of type 1 diabetes iden-
tiﬁed by ICD-9-CM codes. The data were analyzed using
SPSS 10.0. The association between drug and medical
costs was determined using Pearson correlation. The 
signiﬁcance level was set at the 95% conﬁdence interval.
Linear regression analysis was conducted to predict
medical costs from drug costs. The dependent variable
was the logarithm of medical costs. The independent 
variables were drug costs, length of service, additional
therapy, age and gender. RESULTS: There was a statisti-
cally signiﬁcant inverse correlation between drug costs
and medical costs (r = -0.229, CI: -0.33 - -0.13). In 
the regression model the following independent variables
were determined to be predictors of medical costs: drug
costs (b = 0.00, CI: -0.003 - -0.002), additional therapy
(b = -0.362, CI: -0.51 - -0.21) and length of service 
(b = 0.002, CI: 0.001 - 0.002). Age and gender were not
found to be signiﬁcant predictors of medical costs. 
CONCLUSIONS: The inverse correlation implies that if
type 1 diabetes is managed appropriately with drugs, 
the medical costs may be reduced. This may reduce the
overall health care expenditures. The regression model
also showed that as drug costs increased medical costs
decreased. The regression model can be used to predict
the future medical costs if the drug costs are known.
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Cost of illness estimates for chronic diseases can be under-
estimated if only costs related to diagnosis and treatment
of that disease are measured. This underestimation results
from overlooking costs associated with secondary conse-
quences of the disease such as complications and co-
morbid conditions associated with the disease.
OBJECTIVE: Two methods for estimating medical care
costs of diabetes were compared: an “attributable”
method” and a “case-control” method. METHODS: The
study population was all diabetic patients in the 1999
Medical Expenditure Panel Survey, a nationally represen-
tative series of probability surveys on the use and cost of
medical care in the United States. “Attributable” costs
were estimated by summing costs speciﬁcally associated
with diabetes. “Case-control” costs were estimated by
subtracting costs between diabetic cases and non-diabetic
controls which were matched on age, gender, race, and
number of comorbid conditions not related to diabetes.
Costs were summarized for pharmacy, hospital inpatient,
outpatient, and emergency room care and reported in
1999 dollars. RESULTS: The total cost of illness was
$3046 per patient using case-control method compared
to $1151 per patient using the attributable method. The
case-control method found costs to be higher for all cat-
egories of care, with the largest being hospital inpatient
costs. Cost differences were statistically signiﬁcant for 
all categories except for emergency room care. CON-
CLUSIONS: Diabetic “attributed” costs accounted for
only 39% of the total difference in health care costs
between diabetics and matched controls. Patients with
diabetes use more medical services than controls, but a
large portion of this care is not speciﬁcally attributed to
diabetes.
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OBJECTIVES: Few studies have compared the short-term
costs to achieve recommended glycemic goals in Type-2
diabetes. We developed a decision analysis to project costs
of treating patients to glycemic goals from a managed
care perspective and evaluated feasibility of summarizing
this model in an aggregate linear regression (LR) form.
METHODS: A literature-based decision model simulated
the 3-year treatment costs (medical, pharmacy, adverse
events) to achieve an HbA1c < 7% for three cohorts of
patients newly diagnosed with Type-2 diabetes and failing
lifestyle changes. Each cohort was assigned to a different
ﬁrst-line therapy: glipizide GITS, generic metformin, or
rosiglitazone. Add-on treatments occurred as necessary to
achieve glycemic control. To summarize the model in a
LR form, we ﬁrst conducted Monte Carlo simulations
(MCS) of the model for each therapy. The costs (depen-
dent variables) estimated via 1000 MCS runs were then
summarized through OLS regressions, using the most sen-
sitive and/or relevant variables from the decision model
as predictors. We then compared the results generated via
each method. RESULTS: The projected cost differences
between agents with the decision analysis and the aggre-
gate LR form were identical: -$558 (glipizide GITS vs.
metformin), -$1557 (glipizide GITS vs. rosiglitazone),
and -$998 (metformin vs. rosiglitazone). The R2 of 
the LR ranged between .49 and .53. Both methods led 
to identical conclusions regarding which agent was
least/most expensive in >97% of cases. The accordance
